重组人脑利钠肽治疗急性左心衰患者血浆NT-proBNP的变换趋势研究

Study on the transformation trend of plasma NT-proBNP in patients with acute left heart failure treated by recombinant human brain natriuretic peptide

目的探讨重组人脑利钠肽（新活素）治疗急性左心衰后其血浆NT—proBNP的变换趋势。方法回顾性分析于2011年4月～2013年6月入我院进行治疗的56例急性左心衰患者的临床资料，按治疗方法将其分为观察组和对照组。对照组行常规抗心衰治疗，观察组以此为基础给予新活素治疗，对两组患者的治疗总有效率以及血浆NT—proBNP的变换趋势进行比较。结果两组治疗总有效率比较（X2=9．1636，P=0．0025）；观察组血浆NT—proBNP水平比较（t=2．6744，P=0．0099）。在症状缓解时间、平均住院时间方面比较，差异有统计学意义（P〈0．05）。结论采用重组人脑利钠肽对急性左心衰患者进行治疗可明显改善患者的症状和体征，在症状缓解时间和住院时间方面均优于常规治疗，值得临床借鉴和推广。

Objective To explore the transformation trend of plasma NT-proBNP in patients with acute left heart failure treated by recombinant human brain natriuretic peptide（Xinhuosu）. Methods A retrospective analysis was conducted on the clinical data of 56 cases of acute left heart failure treated in our hospital from Apr. 2011 to Jun. 2013. The patients were assigned to the observation group and the control group according to the treatment methods. The control group was given routine heart failure treatment and the observation group was given Xinhuosu treatment on the basis of routine heart failure treatment. The total effective rate and transformation trend of plasma NT-proBNP were compared between the two groups. Results The two groups had different total effective rate（x^2=9.1636, P=0.0025） and different plasma NT-proBNP（t=2.6744, P=0.0099）. The two groups also had significant difference with regard to the symptom alleviation time and average hospital stay, with statistical significanee（P 〈 0.05）. Conclusion Application of recombinant human brain natriuretic peptide for treatment of patients with acute left heart failure can significantly improve the symptoms and signs, with better efficacy than routine treatment with regard to the symptom alleviation time and hospital stay, which is worthy of clinical reference and promotion.